Telix Pharmaceuticals (TLX) Stock Price, Quote, News & History | Benzinga

Telix Pharmaceuticals Ltd (TLX) Stock Price, Quote, News & History

TLXNASDAQ

Trade with Public

Trade with Public

$11.29

-0.085-0.75%

At close: Aug 28, 5:00 PM EST

$11.31

0.020.18%

After Hours: Aug 27, 9:25 AM EST

OverviewNews Earnings Forecast Events Price Targets Financials Sentiment Ownership Compare Stock Report

Key Statistics

Open

$11.47

Close

$11.29

Volume / Avg.

88.53K / 162.50K

Day Range

$11.21 - $11.47

52 Wk Range

6.28 - 12.50

Market Cap

$3.84B

P/E Ratio

115.30

Dividend Yield

-

Exchange

NASDAQ

RSI

50

Short Interest

0.08%

Days to Cover

2.31

Recent Telix Pharmaceuticals Limited News

Why Is Regeneron Stock Sinking Monday?

Regeneron melanoma combo trial missed its main goal against Keytruda despite longer progression-free survival in the high-dose arm.

Vandana Singh

JPMorgan, Allogene Therapeutics And Other Big Stocks Moving Lower In Tuesday's Pre-Market Session

US stock futures mixed, Nasdaq 100 up over 50 points. JPMorgan shares down 3.1% after beating earnings but missing sales estimates. Other stocks also down in pre-market trading.

Avi Kapoor

Telix Pharma Gains As Regeneron Tie-Up Targets Solid Tumor Programs

Telix collaborates with Regeneron, targeting radiopharmaceutical development, with milestones up to $2.1 billion and royalties.

Vandana Singh

Telix Seeks Reset With FDA Filing While Sales Growth Holds Steady

FDA accepts Telix NDA for Pixclara for brain cancer imaging, analysts see confidence rebuild amid steady sales growth.

Vandana Singh

Why Is Telix Pharma Stock Soaring Tuesday?

Telix Pharma stock climbs on strong Q1 growth and Phase 3 study success. Analysts maintain Buy ratings with price targets up to $22.00.

Vandana Singh

Financials

Quarterly

Annual

Name

Revenue Change
Gross Change
EBITDA Change
EBIT Change
Earnings Change

Cash Flows

Operating Cash Flow (TTM)

-

Investing Cash Flow (TTM)

-60.78M

Financing Cash Flow (TTM)

117.63M

Free Cash Flow (TTM)

-46.79M

Capital Expenditure (TTM)

-34.79M

Net Change in Cash (TTM)

44.84M

Analyst Trends and Forecast

4

Apr

3

Jul

1

Aug

Buy

Hold

Sell

Strong Sell

Analyst Rating and Forecast

4.1

Buy

Strong Buy

Buy

Hold

Sell

Strong Sell

Valuation Metrics

Enterprise Value

$4.15B

PE Ratio (TTM)

115.30

PE Ratio (FWD)

161.29

PEG Ratio (TTM)

-

PS Ratio (TTM)

4.19

PB Ratio (TTM)

7.93

Earnings Yield % (TTM)

0.87%

Earnings Yield % (FWD)

0.62%

EV / EBITDA (TTM)

56.89

Price / EBITDA (TTM)

51.38

Price / Free Cash Flow (TTM)

-

Book Value / Share

$1.44

Company Debt

Total Debt

$516.39M

LT Debt

$504.88M

LT Debt Issuance (TTM)

$587.98M

LT Debt Repayment (TTM)

-$472.85M

Total Cash

$251.91M

Debt to Equity

1.19

Issuance of Debt (TTM)

$115.13M

Repayment of Debt (TTM)

-$472.85M

Key Statistics

Open

$11.47

Close

$11.29

Volume / Avg.

88.53K / 162.50K

Day Range

$11.21 - $11.47

52 Wk Range

6.28 - 12.50

Market Cap

$3.84B

P/E Ratio

115.30

Dividend Yield

-

Exchange

NASDAQ

RSI

50

Short Interest

0.08%

Days to Cover

2.31

About

Sector

Health Care

Industry

Biotechnology

Telix develops radiopharmaceuticals to manage cancer. Radiopharmaceuticals are radioisotopes bound to molecules that can target specific cells. At low doses, these drugs can bind to specific cancer cells with radiation, and then positron emission tom...

Show More

Edge Rankings

Stock Score Locked: Want to See it?

Benzinga Rankings give you vital metrics on any stock – anytime.

Reveal Full Score

Compare

EPS worse than industry

Earnings Per Share

EPS is the portion of a company's profit allocated to each outstanding share of common stock. It is a key metric for investors to assess a company's profitability.

Earnings Per Share

EPS is the portion of a company's profit allocated to each outstanding share of common stock. It is a key metric for investors to assess a company's profitability.

EPS worse than industry

FAQ

Q

How do I buy Telix Pharmaceuticals (TLX) stock?

A

You can purchase shares of Telix Pharmaceuticals (NASDAQ:TLX) through any online brokerage.

View our list of the best stock brokerages

Q

Who are Telix Pharmaceuticals (TLX) competitors?

A

Other companies in Telix Pharmaceuticals’s space includes: AbbVie Inc (NYSE:ABBV), Amgen Inc (NASDAQ:AMGN), Gilead Sciences Inc (NASDAQ:GILD), Vertex Pharmaceuticals Inc (NASDAQ:VRTX) and Regeneron Pharmaceuticals Inc (NASDAQ:REGN).

Q

What is the forecast, or price target, for Telix Pharmaceuticals (TLX) stock?

A

Telix Pharmaceuticals has a consensus price target of $21.20.

Q

What is the current price for Telix Pharmaceuticals (TLX)?

A

The stock price for Telix Pharmaceuticals (NASDAQ: TLX) is $11.31 last updated August 27, 2026 at 9:25 AM EDT.

Q

Does Telix Pharmaceuticals (TLX) pay a dividend?

A

There are no upcoming dividends for Telix Pharmaceuticals.

Q

When is Telix Pharmaceuticals (NASDAQ:TLX) reporting earnings?

A

Telix Pharmaceuticals does not have any upcoming earnings scheduled.

Q

Is Telix Pharmaceuticals (TLX) going to split?

A

There is no upcoming split for Telix Pharmaceuticals.

Q

What sector and industry does Telix Pharmaceuticals (TLX) operate in?

A

Telix Pharmaceuticals is in the Health Care sector and Biotechnology industry. They are listed on the NASDAQ.